Perseus Proteomics Inc.

University of Miyazaki

Fujita Health University

Institute for Antibodies Co., Ltd.

Other

Amano Enzyme Inc.

Osaka Prefecture University Public Corporation

Japan As Represented by Director-general of National Institute of Infectious Diseases

Gene Kurosawa

Yoshikazu Kurosawa

Kazuhiro Morishita

Yoshinori Ukai

Katsuyuki Mitomo

Lilin Zhang

Fumiko Nomura

Yukio Sudo

Mariko Sumitomo

Masachika Azuma

Atsushi Sugioka

Nobuhiro Takahashi

Kazuhiro Suzuki

Keiko Ogawa

Katsushi Kouda

Yoshitaka Iba

Motohide Takahashi

Yasushi Akahori

Shunji Kozaki

Sari Fujiyama

Mamoru Shiraishi

Maiko Kurosawa

Masafumi Mukamoto

Tomoko Kohda

Nobuhiro Hayashi

Akihiko Takasaki

Miwa Morita

Susumu Tsustumi

Kazuko Kaneda

Kazuki Matsuda

Chiho Muramatsu

Miho Tanaka

Mototaka Sugiura

Noriko Satou

Susumu Tsutsumi

It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

Antibody which specifically reacts with human integrin A6B4

An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

Antibody capable of specifically recognizing transferrin receptor

The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.

Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same

To provide a method for detecting cellular DNA damage by specifically recognizing molecules responsive to DNA strand breaks. A method for detecting DNA damage in cells, which comprises administering in vivo, to cells, an antibody against a cell membrane surface antigen that is expressed in cells undergoing DNA strand breaks to a greater extent than in cells not undergoing DNA strand breaks in an environment that causes DNA damage, and analyzing the expression status of the cell membrane surface antigen.

Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D

Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.

Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Anti-IgSF4 antibody and utilization of the same

Growing community of inventors

Tokyo, Japan

Gene Kurosawa